Form 4: Monopar Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Raymond Anderson, a Director of Monopar Therapeutics, sold 3,142 shares of common stock on August 25, 2026.
Summary
- Open-market sale: disposed of 694 Common Stock at $110.04 ($76,368) on August 25, 2026; holds 26,169 after (Direct).
- Open-market sale: disposed of 646 Common Stock at $110.07 ($71,105) on August 25, 2026; holds 25,523 after (Direct).
- Open-market sale: disposed of 1,802 Common Stock at $113.05 ($203,716) on August 25, 2026; holds 23,751 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $351,189 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Raymond Anderson — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-25 | Open-market sale | Common Stock | 694 | $110 | $76.4K | 26,169 |
| 2026-08-25 | Open-market sale | Common Stock | 646 | $110 | $71.1K | 25,523 |
| 2026-08-25 | Open-market sale | Common Stock | 1,802 | $113 | $203.7K | 23,751 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-25 | Open-market sale (694 shares) |
| 2026-08-25 | Open-market sale (646 shares) |
| 2026-08-25 | Open-market sale (1,802 shares) |
Keywords
insider transaction, Form 4, MNPR, Monopar Therapeutics, bearish, Raymond Anderson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.